Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences

Figures & data

Table 1 The demographic data

Characteristics	n (%) or mean±SD (171 patients, 201 eyes)
Gender
Male	87 (50.9)
Female	84 (49.1)
Mean age at PCV diagnosis, years	68.46±9.24
Laterality
Right eye	80 (46.8)
Left eye	61 (35.7)
Both eyes	30 (17.5)
At baseline
BCVA (logMAR)	0.61±0.51
CRT (µm)	290.39±112.15

Abbreviations: PCV, polypoidal choroidal vasculopathy; BCVA, best-corrected visual acuity; CRT, central retinal thickness; logMAR = Logarithm of the minimum angle of resolution.

Table 2 The cumulative number of patients for each group at each year

Year	n (%)
First year
Combination group	34 (16.9)
Anti-VEGF group	167 (83.1)
Second year
Combination group	47 (23.7)
Anti-VEGF group	151 (76.3)
Third year
Combination group	57 (33.3)
Anti-VEGF group	114 (66.7)
Fourth year
Combination group	55 (41.0)
Anti-VEGF group	79 (59.0)

Abbreviation: anti-VEGF, anti-vascular endothelial growth factor.

Table 3 The number of injections at each year

Year	Combination	Anti-VEGF	P-value
First year	3.65±2.31	3.04±2.00	0.116
Second year	1.85±1.99	1.22±1.82	0.056
Third year	1.83±2.04	1.97±2.23	0.672
Fourth year	2.16±2.22	2.04±2.16	0.743

Abbreviation: anti-VEGF, anti-vascular endothelial growth factor.

Table 4 The number of patients for categories of VA changes at each year

BCVA	Combination (n, %)	Anti-VEGF (n, %)	P-value
First year
BCVA gain >1 line	7 (20.6)	60 (35.9)	0.110
BCVA gain >2 lines	6 (17.6)	47 (28.1)	0.286
BCVA gain >3 lines	5 (14.7)	29 (17.4)	0.807
BCVA loss ≤1 line	25 (73.5)	143 (85.6)	0.124
BCVA loss ≤2 lines	26 (76.5)	151 (90.4)	0.038^*
BCVA loss ≤3 lines	27 (79.4)	152 (91.0)	0.067
Second year
BCVA gain >1 line	13 (27.7)	59 (39.1)	0.169
BCVA gain >2 lines	10 (21.3)	40 (26.5)	0.566
BCVA gain >3 lines	6 (12.8)	11 (13.9)	1.000
BCVA loss ≤1 line	34 (72.3)	122 (80.8)	0.225
BCVA loss ≤2 lines	38 (80.9)	133 (88.1)	0.227
BCVA loss ≤3 lines	38 (80.9)	137 (90.7)	0.073
Third year
BCVA gain >1 line	21 (36.8)	43 (37.7)	1.000
BCVA gain >2 lines	13 (22.8)	30 (26.3)	0.710
BCVA gain >3 lines	7 (12.3)	17 (14.9)	0.816
BCVA loss ≤1 line	46 (80.7)	85 (74.6)	0.445
BCVA loss ≤2 lines	48 (84.2)	95 (83.3)	1.000
BCVA loss ≤3 lines	49 (86.0)	100 (87.7)	0.810
Fourth year
BCVA gain >1 line	18 (32.7)	25 (31.6)	1.000
BCVA gain >2 lines	10 (18.2)	20 (25.3)	0.402
BCVA gain >3 lines	5 (9.1)	11 (13.9)	0.433
BCVA loss ≤1 line	43 (78.2)	53 (67.1)	0.178
BCVA loss ≤2 lines	47 (85.5)	62 (78.5)	0.371
BCVA loss ≤3 lines	48 (87.3)	68 (86.1)	1.000

Abbreviations: VA, visual activity; BCVA, best-corrected visual acuity; anti-VEGF, anti-vascular endothelial growth factor.

Figure 1 The BCVA changes from the baseline for the combination and anti-VEGF groups at each year.

Abbreviations: BCVA, best-corrected visual acuity; anti-VEGF, anti-vascular endothelial growth factor.

Figure 2 The CRT changes from the baseline for the combination and anti-VEGF groups at each year.

Note: *P-value with statistical significance.
Abbreviations: CRT, central retinal thickness; anti-VEGF, anti-vascular endothelial growth factor.